- Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform.
- The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies.
- This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers.
Twist Bioscience comes into this agreement with its shares at $48.54 and a return of 49.9% year to date, and 18.9% over the past year. Over three years the return is very large at around 7x, while over five years the stock shows a 65.7% decline, underscoring how volatile the ride has been for long term holders.
This licensing and equity deal with Invenra gives Twist a broader toolkit in biologics discovery that could matter for how customers view its platform over time. For investors watching NasdaqGS:TWST, the agreement adds another piece to the story around how Twist is trying to grow its role in antibody and protein engineering across the biotechnology sector.
Stay updated on the most important news stories for Twist Bioscience by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Twist Bioscience.
We've flagged 2 risks for Twist Bioscience. See which could impact your investment.
This agreement adds a specialized bispecific antibody platform on top of Twist Bioscience's existing in vivo, in vitro and AI-enabled discovery tools, which could make its offering more attractive to biotech and pharma customers that want a single partner for complex antibody programs. By becoming co-exclusive provider of Invenra's B Body platform, Twist is tying a differentiated piece of antibody engineering into its high throughput DNA and protein workflows rather than trying to build this capability from scratch.
How This Fits Into The Twist Bioscience Narrative
- The deal supports the idea from the community narrative that Twist is pushing hard on commercial expansion, since it broadens the menu of services it can sell into large pharma, biotechnology and diagnostics customers.
- It also tests the narrative's concern about ongoing losses, as Twist is committing cash and stock outlays plus a 20% royalty to Invenra on license revenue, which could weigh on profitability if bispecific programs do not ramp meaningfully.
- The equity stake of about 6% in Invenra and Twist receiving all bispecific discovery and license revenue introduce an ownership and revenue sharing structure that is not fully reflected in the earlier narrative framing of the business model.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Twist Bioscience to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
- ⚠️ Twist remains unprofitable and is not forecast to become profitable over the next 3 years, so new deals that involve cash, stock issuance and revenue sharing increase execution risk if they do not scale as planned.
- ⚠️ There has been significant insider selling over the past 3 months, which some investors may read cautiously when the company is also issuing stock as part of this licensing and equity transaction.
- 🎁 Revenue is forecast to grow 13.38% per year, and adding bispecific antibody services may help support that growth if customers adopt the broader discovery offering.
- 🎁 Earnings have grown 2.1% per year over the past 5 years, and management is using partnerships like this one to try to deepen relationships with large pharma peers such as Amgen, Pfizer or Merck, as well as compete more directly with platforms from companies like Seagen or Regeneron in complex antibody engineering.
What To Watch Going Forward
From here, you may want to watch how quickly Twist converts this bispecific capability into signed discovery projects, license deals and disclosed milestones, since Twist receives all discovery and license revenue and pays Invenra a 20% royalty only on license revenue. The scale of equity dilution from issuing US$28.8 million of stock, the performance of the roughly 6% stake in Invenra and any commentary on upcoming bispecific programs during future shareholder calls will also be important. Given recent insider selling and the share price volatility in NasdaqGS:TWST, updates on customer adoption and any comparisons management makes to antibody discovery peers will help you judge whether this agreement is strengthening Twist's position or simply adding complexity.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Twist Bioscience, head to the community page for Twist Bioscience to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com